Theravance Biopharma Q3 2023 Earnings Report $9.59 -0.14 (-1.44%) (As of 12/20/2024 05:16 PM ET) Earnings HistoryForecast Theravance Biopharma EPS ResultsActual EPS-$0.17Consensus EPS -$0.21Beat/MissBeat by +$0.04One Year Ago EPSN/ATheravance Biopharma Revenue ResultsActual Revenue$15.69 millionExpected Revenue$15.59 millionBeat/MissBeat by +$100.00 thousandYoY Revenue GrowthN/ATheravance Biopharma Announcement DetailsQuarterQ3 2023Date11/7/2023TimeN/AConference Call ResourcesTBPH Earnings History The #1 Coin for November 2024 (Ad)Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Theravance Biopharma Earnings HeadlinesTheravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare ConferenceDecember 17, 2024 | prnewswire.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus Price Target from AnalystsDecember 14, 2024 | americanbankingnews.comWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.December 22, 2024 | Behind the Markets (Ad)Theravance Biopharma to Participate in an Upcoming Investor ConferenceNovember 20, 2024 | prnewswire.comTheravance Biopharma’s Third Quarter 2024 Financial InsightsNovember 14, 2024 | markets.businessinsider.comTheravance Biopharma (TBPH) Receives a Hold from Evercore ISINovember 14, 2024 | markets.businessinsider.comSee More Theravance Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Theravance Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theravance Biopharma and other key companies, straight to your email. Email Address About Theravance BiopharmaTheravance Biopharma (NASDAQ:TBPH) is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.View Theravance Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
